137 related articles for article (PubMed ID: 8380547)
1. Estrogens, progesterone, and endometrial cancer.
Jick SS; Walker AM; Jick H
Epidemiology; 1993 Jan; 4(1):20-4. PubMed ID: 8380547
[TBL] [Abstract][Full Text] [Related]
2. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens.
Cushing KL; Weiss NS; Voigt LF; McKnight B; Beresford SA
Obstet Gynecol; 1998 Jan; 91(1):35-9. PubMed ID: 9464717
[TBL] [Abstract][Full Text] [Related]
3. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.
Chlebowski RT; Anderson GL; Sarto GE; Haque R; Runowicz CD; Aragaki AK; Thomson CA; Howard BV; Wactawski-Wende J; Chen C; Rohan TE; Simon MS; Reed SD; Manson JE
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26668177
[TBL] [Abstract][Full Text] [Related]
4. Hormone replacement therapy and endometrial cancer risk: a meta-analysis.
Grady D; Gebretsadik T; Kerlikowske K; Ernster V; Petitti D
Obstet Gynecol; 1995 Feb; 85(2):304-13. PubMed ID: 7824251
[TBL] [Abstract][Full Text] [Related]
5. Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer.
Comerci JT; Fields AL; Runowicz CD; Goldberg GL
Gynecol Oncol; 1997 Mar; 64(3):425-30. PubMed ID: 9062144
[TBL] [Abstract][Full Text] [Related]
6. Continuous HRT with oestrogen plus progestogen is linked to reduced risk of endometrial cancer.
Mayor S
BMJ; 2015 Dec; 351():h6627. PubMed ID: 26645093
[No Abstract] [Full Text] [Related]
7. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group.
Brinton LA; Hoover RN
Obstet Gynecol; 1993 Feb; 81(2):265-71. PubMed ID: 8380913
[TBL] [Abstract][Full Text] [Related]
8. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group.
Woodruff JD; Pickar JH
Am J Obstet Gynecol; 1994 May; 170(5 Pt 1):1213-23. PubMed ID: 8178840
[TBL] [Abstract][Full Text] [Related]
9. Risk of endometrial cancer following estrogen replacement with and without progestins.
Weiderpass E; Adami HO; Baron JA; Magnusson C; Bergström R; Lindgren A; Correia N; Persson I
J Natl Cancer Inst; 1999 Jul; 91(13):1131-7. PubMed ID: 10393721
[TBL] [Abstract][Full Text] [Related]
10. Endometrial cancer risk after discontinuing use of unopposed conjugated estrogens (California, United States).
Finkle WD; Greenland S; Miettinen OS; Ziel HK
Cancer Causes Control; 1995 Mar; 6(2):99-102. PubMed ID: 7749058
[TBL] [Abstract][Full Text] [Related]
11. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results.
Pickar JH; Yeh IT; Wheeler JE; Cunnane MF; Speroff L
Fertil Steril; 2003 Nov; 80(5):1234-40. PubMed ID: 14607581
[TBL] [Abstract][Full Text] [Related]
12. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
Pickar JH; Yeh I; Wheeler JE; Cunnane MF; Speroff L
Fertil Steril; 2001 Jul; 76(1):25-31. PubMed ID: 11438315
[TBL] [Abstract][Full Text] [Related]
13. Postmenopausal unopposed estrogens. Characteristics of use in relation to the risk of endometrial carcinoma.
Herrinton LJ; Weiss NS
Ann Epidemiol; 1993 May; 3(3):308-18. PubMed ID: 8275205
[TBL] [Abstract][Full Text] [Related]
14. Endometrial cancer and hormone-replacement therapy in the Million Women Study.
Beral V; Bull D; Reeves G;
Lancet; 2005 Apr 30-May 6; 365(9470):1543-51. PubMed ID: 15866308
[TBL] [Abstract][Full Text] [Related]
15. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study.
Kaufman DW; Palmer JR; de Mouzon J; Rosenberg L; Stolley PD; Warshauer ME; Zauber AG; Shapiro S
Am J Epidemiol; 1991 Dec; 134(12):1375-85; discussion 1396-401. PubMed ID: 1663700
[TBL] [Abstract][Full Text] [Related]
16. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
[TBL] [Abstract][Full Text] [Related]
17. Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens.
Lundström E; Wilczek B; von Palffy Z; Söderqvist G; von Schoultz B
Climacteric; 2001 Mar; 4(1):42-8. PubMed ID: 11379377
[TBL] [Abstract][Full Text] [Related]
18. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women.
Beresford SA; Weiss NS; Voigt LF; McKnight B
Lancet; 1997 Feb; 349(9050):458-61. PubMed ID: 9040575
[TBL] [Abstract][Full Text] [Related]
19. Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer.
Jick SS; Hagberg KW; Kaye JA; Jick H
Obstet Gynecol; 2009 Jan; 113(1):74-80. PubMed ID: 19104362
[TBL] [Abstract][Full Text] [Related]
20. Effects of estrogen with and without progestin on urinary incontinence.
Hendrix SL; Cochrane BB; Nygaard IE; Handa VL; Barnabei VM; Iglesia C; Aragaki A; Naughton MJ; Wallace RB; McNeeley SG
JAMA; 2005 Feb; 293(8):935-48. PubMed ID: 15728164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
